Skip to main content

Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions

Objective

Colorectal cancer (CRC) is the third most common cancer in Europe with c. 420,000 cases and 150,000 related deaths in 2012. Of total CRC cases, it is estimated that approximately 50-55 % harbour RAS mutations. Current treatment for RAS mutant (mt) metastatic(m) CRC is primarily based on 5-fluoruracil based chemotherapy +/- bevacizumab. However, there are currently limited treatment options once cancers have become resistant. Moreover, while therapy optimization strategies in RAS wild-type CRC patients are feasible, targeted treatment of microsatellite stable (MSS) RAS mt disease is difficult and has not evolved significantly in recent years. COLOSSUS will deliver novel concepts for disease-mechanism based patient stratification in MSS RAS mt mCRC to address the need for stratified or personalised therapeutic interventions in this setting. The consortium will integrate multidimensional and longitudinal omics data to identify new MSS RAS mt specific subtypes with unique signalling dependences. We will harness the power of systems biomedicine, network analysis and computational modelling to identify new actionable pathways, biomarkers and targets across subtypes. These targets will be interrogated in state of the art pre-clinical patient derived xenograft studies. Newly described MSS RAS mt classifiers will be validated as novel patient stratification tools within the COLOSSUS trial. SME partners will develop clinically relevant and commercially viable assays for outcome prediction and stratification of MSS RAS mt patients based on novel classifiers. The impact of assays on CRC associated healthcare costs will further be assessed. Patient associations will be included and the proposal will consider regulatory aspects and commercialisation opportunities, in particular for participating SMEs. mCRC is a complex disease having high prevalence and high economic impact both within a European and global context.

Call for proposal

H2020-SC1-2017-Two-Stage-RTD
See other projects for this call

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Address
Saint Stephen's Green 123
2 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 493 066,94

Participants (13)

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Spain
EU contribution
€ 986 982,65
Address
Calle Nazaret 115-117
08035 Barcelona
Activity type
Research Organisations
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland
EU contribution
€ 349 172,88
Address
Belfield
4 Dublin
Activity type
Higher or Secondary Education Establishments
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
United Kingdom
EU contribution
€ 295 455,64
Address
Old Brompton Road 123
SW7 3RP London
Activity type
Higher or Secondary Education Establishments
VIB VZW
Belgium
EU contribution
€ 695 602,23
Address
Rijvisschestraat 120
9052 Zwijnaarde - Gent
Activity type
Research Organisations
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Germany
EU contribution
€ 123 448
Address
Seminarstrasse 2
69117 Heidelberg
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI TORINO
Italy
EU contribution
€ 461 351,98
Address
Via Giuseppe Verdi 8
10124 Torino
Activity type
Higher or Secondary Education Establishments
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 175 482,79
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
CANCER TRIALS IRELAND CLG
Ireland
EU contribution
€ 200 853,95
Address
Innovation House Dcu Alpha Finglas Road Old
D11 KXN4 Dublin 11
Activity type
Other
OPTIMATA LTD

Participation ended

Israel
EU contribution
€ 38 361,60
Address
20 Zichron Yaa'kov St.
6299920 Tel Aviv
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GENEXPLAIN GMBH
Germany
EU contribution
€ 281 865,03
Address
Am Exer 19 B
38302 Wolfenbuttel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HALIODX
France
EU contribution
€ 411 141,60
Address
163 Avenue De Luminy Parc Scientifique De Luminy Luminy Biotec Entreprises
13288 Marseille
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EPIGENOMICS AG
Germany
EU contribution
€ 226 916,26
Address
Kleine Praesidentenstr 1
10178 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PINTAIL LTD
Ireland
EU contribution
€ 256 657,95
Address
Springhill Avenue 77
A94 K542 Blackrock
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)